What Is Outlook 2019?
Executive Summary
A New Year and a new look. For 2019 we have merged the Scrip 100 with In Vivo’s annual preview magazine, creating a new beast known as Outlook. This encompasses all the best aspects of both issues and covers more topic areas than ever before.
Outlook 2019 includes annual league tables for both the top 100 biopharmaceutical and top 100 medical technology companies, ranking the leaders of each sector by their 2017 full-year financial performance. A full analysis of the biopharmaceutical and medtech sectors’ financial data can be found on the Outlook 2019 hot topic page.
Monetary scrutiny is not the only reason to investigate the content of Outlook 2019. Bringing in something new, the Outlook chapter includes detailed forward-looking articles that focus on the state of play for the biopharma and medtech industries in the coming year. Written by In Vivo’s executive editors William Looney and Ashley Yeo, the Outlook section covers a lot of ground to help industry execs get up to speed with the biggest changes, challenges and trends that are expected to disrupt the life sciences sector over the next 12 months.
Outlook 2019 has all the favorites from the previous Scrip 100 issue, including chapters on business, leadership, R&D, clinical trials and regulation. But this year, our special edition also includes sections on medtech, generics and biosimilars, plus gene therapy.
Highlights inside Outlook 2019 include: an exclusive interview with the 2018 Scrip Award’s Lifetime Achievement winner, Professor Sir John Bell; a closer look at the complex biosimilar market in Asia; interviews with C-suite members from Regeneron Pharmaceuticals Inc., Novartis AG, AstraZeneca PLC, GE Healthcare, Philips, BC Platforms and more; insights from the head of the Danish Medicines Agency, Thomas Senderovitz; a review of pharma’s M&A activity in 2018 and expectations for the year ahead; and articles exploring the complex arena of cell and gene manufacturing and logistics.